Analysts Set MediWound Ltd. (NASDAQ:MDWD) Price Target at $33.50

MediWound Ltd. (NASDAQ:MDWD) has been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $33.50.

Several research firms recently commented on MDWD. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective (up from $31.00) on shares of MediWound in a report on Friday, November 21st. Wall Street Zen upgraded shares of MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th.

Institutional Investors Weigh In On MediWound

Institutional investors have recently added to or reduced their stakes in the company. Rosalind Advisors Inc. lifted its holdings in MediWound by 84.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock worth $13,498,000 after buying an additional 341,993 shares during the period. Meitav Investment House Ltd. increased its position in MediWound by 825.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock valued at $5,241,000 after buying an additional 260,116 shares in the last quarter. Millennium Management LLC increased its holdings in shares of MediWound by 355.6% during the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after acquiring an additional 136,884 shares in the last quarter. Menora Mivtachim Holdings LTD. raised its holdings in MediWound by 348.8% in the third quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock worth $1,415,000 after buying an additional 61,039 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of MediWound during the third quarter valued at approximately $1,042,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Stock Up 4.6%

MDWD opened at $17.00 on Friday. The company’s 50-day moving average price is $18.17 and its two-hundred day moving average price is $18.27. MediWound has a twelve month low of $14.14 and a twelve month high of $22.50. The stock has a market cap of $218.28 million, a price-to-earnings ratio of -8.95 and a beta of 0.07.

MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.57. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%.The firm had revenue of $5.43 million for the quarter, compared to analyst estimates of $6.56 million. As a group, sell-side analysts anticipate that MediWound will post -2.66 earnings per share for the current year.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.